As clinicians, we are trained to make a positive diagnosis of irritable bowel syndrome (IBS), by using a combination of the most pertinent parts of the patient history, physical examination findings, and a limited panel of blood tests. However, in routine practice, it is not uncommon for a diagnosis of IBS to be made by exclusion, following extensive and negative investigations. 1 One possible reason for this is the lack of a non-invasive diagnostic test for IBS. The current gold standard is symptom-based diagnostic criteria, developed in the 1970s, 2 and modified over time. The latest of these, the Rome III criteria (Table 1) , were published in 2006. 3 However, symptom-based criteria perform only modestly in predicting a diagnosis of IBS. 4, 5 Partly as a result of this unsatisfactory situation, research has focused on developing novel biomarkers (physiological mechanisms, genes, proteins, or metabolites) to aid in the diagnosis of IBS. A non-invasive biomarker that accurately predicts a diagnosis of IBS would be a significant advance, but are we any closer to developing one? A recent systematic review and meta-analysis summarized the various approaches to diagnosing IBS, 6 using pooled likelihood ratios (LRs) to assess the diagnostic accuracy of available methods. As a rule of thumb for readers of this article, a positive LR 410 is useful for ruling in disease, whereas a negative LRo0.1 is useful for ruling out disease. A serum-based 10 biomarker panel (including interleukin-1ß and anti-tissue transglutaminase), assessed in two separate studies, 7, 8 demonstrated pooled positive and negative LRs of 3.03 (95% confidence interval (CI): 1.49-6.17) and 0.52 (95% CI: 0.43-0.64), respectively. In the later study, 8 an additional 24 biomarkers were added to the original 10 biomarker panel. However, the 34 biomarker panel did not perform any better, with positive and negative LRs of 2.28 (95% CI: 1.71-3.17) and 0.30 (95% CI: 0.21-0.42), respectively.
In a more recent study, 9 the accuracy of two serum biomarkers, antibodies to cytolethal distending toxin B (CdtB), a bacterial toxin commonly produced by Campylobacter jejuni, and vinculin, a host cell adhesion protein with which CdtB is known to cross-react, were assessed in terms of their ability to differentiate between diarrhea-predominant IBS, inflammatory bowel disease, celiac disease, and health. The biomarkers performed best in differentiating diarrhea-predominant IBS from inflammatory bowel disease. Using a cutoff level of anti-CdtB antibodies ≥ 2.80, positive and negative LRs were 5.2 and 0.6, respectively. Using a cutoff level ≥ 1.68 for anti-vinculin antibodies, positive and negative LRs were 2.0 and 0.8, respectively. Fecal biomarkers, in the form of volatile organic metabolites, chemicals released in feces, which can undergo change in the presence of organic disease, have also been evaluated in one small study in differentiating diarrheapredominant IBS from active inflammatory bowel disease. 10 Positive and negative LRs were 4.83 (95% CI: 3.36-7.14) and 0.04 (95% CI: 0.01-0.21), respectively. 6 What is noticeable in these studies is that individual biomarkers appear to perform only moderately well in differentiating IBS from organic disease and, at present, are probably no better, and may be considerably more expensive, than symptom-based criteria, which cost nothing to implement in the clinic. The Rome III criteria had a positive and negative LR of 3.39 (95% CI: 2.96-3.88) and 0.47 (95% CI: 0.41-0.53), respectively. 5 One possible reason why individual biomarkers perform sub-optimally is that IBS is a complex heterogeneous disorder, with a multifactorial etiology, and it is therefore unlikely that a single biomarker will be able to differentiate IBS from organic disease with the degree of accuracy required from a diagnostic test.
If an accurate individual biomarker eludes us, are there any other ways that biomarkers could be used? The Kruis statistical model, 11 described 430 years ago, is a scoring system that incorporates the clinical history, physical examination findings, and biomarkers in the form of blood tests, including hemoglobin level, erythrocyte sedimentation rate, and leukocyte count. In the studies that have evaluated this model, which have been summarized in a previous metaanalysis, 4 the pooled positive and negative LRs were 8.63 (95% CI: 2.89-25.8) and 0.26 (95% CI: 0.17-0.41), respectively, approaching the LRs required for a diagnostic test to be useful, and more accurate than any of the individual biomarkers assessed to date. Another study published in 2002 used a combination of the Rome I criteria, fecal calprotectin levels of o10 mg/l, and a small intestinal permeability test, 12 and was able to differentiate IBS from organic disease with a positive LR of 26.4 (95% CI: 11.4-61.9) and a negative LR of 0.51 (95% CI: 0.45-0.56). 6 Combining symptoms and signs with biomarkers seems more intuitive, in that it takes into account the probable composite structure of IBS, and appears to be more accurate than either symptoms or individual biomarkers alone. However, using this approach could result in an overly complex test not practical for use in a clinical setting. How can we overcome this complexity to produce an accurate and easily administrated diagnostic test in the clinic? Latent class analysis (LCA) is a statistical method that can be applied to multivariate categorical data to form sub-types of related cases (latent classes), by recognizing patterns within the data, when using a combination of patient-reported symptoms, clinical examination findings, and biochemical markers. This results in the identification of clinical indicators, which can then be incorporated in to a statistical model, and therefore the development of a diagnostic test that potentially discriminates between IBS and non-IBS profiles with the degree of accuracy needed.
To date, there are few examples of LCA being used in functional gastrointestinal disorders, 13 possibly because of a perceived view that utilizing LCA will also result in a test that is too unwieldy to use easily in routine practice. However, LCA has been used in many other diagnostic situations, and has been shown to be particularly valuable when, as is the case for IBS, an accurate and accepted gold standard test is lacking. [14] [15] [16] [17] In the modern era of smartphones, an easy-touse application (app) could be developed, into which clinical data are inputted by the patient, while sitting in the waiting room, with the results of physical examination and biomarker tests added by the physician. This would then compute a probability of an individual having IBS utilizing LCA methods, and could provide clinicians with a reliable and simple test that is suitable for use in real-time during a busy outpatient clinic.
The performance of the majority of biomarkers is not superior to current symptom-based criteria, and most are experimental at the time of writing. As LCA calculates the probability of having IBS, this means it may be possible to vary the discrimination threshold utilized in the model, using a combination of symptoms, examination findings, and biomarkers, in order to reduce the false positive test rate, minimizing the risk of missed organic disease, and therefore maximizing the clinical utility of the model. This would represent a significant advantage over either symptom-based diagnostic criteria or biomarkers alone. LCA may therefore herald a new and promising approach to diagnosing IBS.
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